Oppenheimer Maintains an 'Outperform' on Trius Therapeutics (TSRX); ICAAC Data Shows Potential Advantages
Tweet
Share
E-mailGet Alerts TSRX Hot Sheet
Price: $13.63 --0%
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Oppenheimer maintains an 'Outperform' on Trius Therapeutics (NASDAQ: TSRX) price target of $12.00.
Analyst, Christopher Holterhoff, said, "On 9/11, TSRX presented new clinical and pre-clinical data, including updated Phase III data from lead product candidate, Tedizolid at the ICAAC conference. Whereas top-line data in 4Q11 showed Tedizolid was non-inferior vs. Zyvox in ABSSSI (10% margin) in terms of early clinical response (79.5% vs. 79.4% Zyvox arm), updated data shows numerical superiority for Tedizolid, with respect to fever-excluded clinical success. Updated safety data shows Tedizolid was associated with fewer treatment-related AE's, with a statistically significant reduction in GI side effects at day 7, fewer incidences of myelosuppression and a lack of MAO (monoamine oxidase-A) inhibition, relative to Zyvox. We anticipate readout from study '113 (1Q13) as the next catalyst."
For an analyst ratings summary and ratings history on Trius Therapeutics click here. For more ratings news on Trius Therapeutics click here.
Shares of Trius Therapeutics closed at $5.82 yesterday.
Analyst, Christopher Holterhoff, said, "On 9/11, TSRX presented new clinical and pre-clinical data, including updated Phase III data from lead product candidate, Tedizolid at the ICAAC conference. Whereas top-line data in 4Q11 showed Tedizolid was non-inferior vs. Zyvox in ABSSSI (10% margin) in terms of early clinical response (79.5% vs. 79.4% Zyvox arm), updated data shows numerical superiority for Tedizolid, with respect to fever-excluded clinical success. Updated safety data shows Tedizolid was associated with fewer treatment-related AE's, with a statistically significant reduction in GI side effects at day 7, fewer incidences of myelosuppression and a lack of MAO (monoamine oxidase-A) inhibition, relative to Zyvox. We anticipate readout from study '113 (1Q13) as the next catalyst."
For an analyst ratings summary and ratings history on Trius Therapeutics click here. For more ratings news on Trius Therapeutics click here.
Shares of Trius Therapeutics closed at $5.82 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald
- Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
